Approximately how many kilograms of fat can be lost with Tilpotide/Mufenda in a month?

Tirzepatide is an innovative drug that has attracted much attention in the fields of diabetes and weight loss in recent years. It is a dual-action GIP/GLP-1 receptor agonist. It was approved by the US FDA in May 2022 for the treatment of patients with type 2 diabetes. On this basis, it was expanded to obesity management under the trade name of Zepbound. Compared with traditional drugs, tilpotide can not only effectively reduce blood sugar, but also significantly control weight. Therefore, it has attracted great attention from the global medical community and patients.

From a mechanism perspective, this drug helps patients reduce caloric intake by delaying gastric emptying, enhancing satiety, and suppressing appetite. At the same time, it can also improve insulin sensitivity, reduce fat accumulation, and have a certain effect on reducing visceral fat and subcutaneous fat. However, the rate of weight loss varies between individuals. Age, eating habits, whether to cooperate with exercise, starting weight and dosage, etc. will all have an impact on the final effect.

Clinical trials have shown that patients who take tilpotide for a long time can lose an average of 15% to 20% of their body weight in about a year and a half. This means that a person who starts weighing between 70kg and 100kg may end up losing 15 to 20kg or more. However, it should be emphasized that these data reflect mid- to long-term effects, not results in just one month. In the first four weeks of use, the patient's weight changes are often still in the initial adaptation stage, and the weight loss may be limited. Some people may only lose about 1-3 kg, and some may even have no significant change.

Therefore, Tilpotide is not a "quick-acting weight loss drug", but a long-term metabolic improvement program. Its value lies in helping patients reduce their weight gradually, stably and sustainably, and avoid the risk of rebound caused by short-term extreme weight loss. For obese patients with diabetes, its more important significance is to improve metabolic status and reduce cardiovascular risk, not just a decrease in weight.

Reference materials:https://www.drugs.com/tirzepatide.html